Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo ...

Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...

Hims & Hers Health, Inc. investors will be delighted, with the company turning in some strong numbers with its latest results. It was overall a positive result, with revenues beat ...

Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong buy ...

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...

Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...

Hims & Hers Health reported its third-quarter results after Monday's closing bell. Here's a look at the details from the ...

Hims & Hers Health, Inc. ( (HIMS) ) has released its Q3 earnings. Here is a breakdown of the information Hims & Hers Health, Inc.

TD Cowen analyst Jonna Kim maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price target of ...

The U.S. stock market experienced a slight downturn on Monday, with the S&P 500 index dipping approximately 0.3%. The Dow ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.